BioMark Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
For the six months, sales was CAD 0.076857 million. Net loss was CAD 0.947025 million compared to CAD 0.467152 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago.